TheraCal LC versus Mineral Trioxide Aggregate for full pulpotomy in cariously exposed mature permanent molars with symptomatic irreversible pulpitis: a randomized clinical trial
Biomaterial Investigations in Dentistry · 21.04.2026 · 13 · 261-270
DOI: 10.2340/biid.v13.45702 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Biomaterial Investigations in Dentistry, online erschienen am 21.04.2026. Verfasst von Vignesh Ravi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric and Preventive Dentistry, Post Graduate Institute of Dental Sciences, Pandit Bhagwat Dayal Sharma University of Health Scienc…. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Preserving pulp vitality is crucial for long-term tooth survival. Pulpotomy, which involves the removal of infected pulp while retaining healthy pulp, helps maintain tooth vitality and function. Although TheraCal LC has shown success as a pulp-capping agent, its use in pulpotomy remains unexplored. This study compared the clinical and radiographic success of TheraCal LC and mineral trioxide aggregate (MTA) in full pulpotomy of mature permanent molars in young patients with symptomatic irreversible pulpitis (SIP). Materials and methods: In this double-blinded, parallel, non-inferiority randomized controlled trial, 72 healthy children (aged 9–14, mean age = 11.72 ± 1.35 years) with cariously exposed mature permanent molars diagnosed with SIP were randomly assigned to receive either TheraCal LC or MTA (n = 36 each). Follow-ups were conducted up to 12 months. Data were analyzed using Mann-Whitney U, Chi-square, and Kaplan-Meier tests (α = 0.05).
Results
At 12 months, MTA showed significantly higher success (ITT – Intention to Treat: 94.4%, PP – Per Protocol: 100%) compared to TheraCal LC (ITT: 75%, PP: 79.4%) (p < 0.05). Seven failures occurred in the TheraCal LC group; none in the MTA group. Two patients in each group were lost to follow-up. Pain scores were significantly lower in the MTA group on days 1, 3, and 5 (p < 0.05).
Conclusions
MTA demonstrated superior outcomes over TheraCal LC for full pulpotomy in young, mature permanent molars with SIP. Statement of clinical relevance: The use of MTA in pulpotomy procedures for mature permanent molars with SIP results in enhanced clinical success rates when compared to TheraCal LC, offering valuable insight for evidence-based treatment planning.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric and Preventive Dentistry, Post Graduate Institute of Dental Sciences, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India.
- Department of Oral and Maxillofacial Pathology, Post Graduate Institute of Dental Sciences, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India.
ORCID-Profile: Vignesh Ravi, Madhur Sharma
Zitieren
APA
Ravi, V., Namdev, R., Singhal, R., Sharma, M., Dayma, C., & Rani, A. (2026). TheraCal LC versus Mineral Trioxide Aggregate for full pulpotomy in cariously exposed mature permanent molars with symptomatic irreversible pulpitis: a randomized clinical trial. Biomaterial Investigations in Dentistry, 13, 261-270. https://doi.org/10.2340/biid.v13.45702
Vancouver
Ravi V, Namdev R, Singhal R, Sharma M, Dayma C, Rani A. TheraCal LC versus Mineral Trioxide Aggregate for full pulpotomy in cariously exposed mature permanent molars with symptomatic irreversible pulpitis: a randomized clinical trial. Biomaterial Investigations in Dentistry. 2026;13:261-270. doi:10.2340/biid.v13.45702
BibTeX
@article{Ravi2026,
author = {Ravi, Vignesh and Namdev, Ritu and Singhal, Ruchi and Sharma, Madhur and Dayma, Charu and Rani, Asha},
title = {TheraCal LC versus Mineral Trioxide Aggregate for full pulpotomy in cariously exposed mature permanent molars with symptomatic irreversible pulpitis: a randomized clinical trial},
journal = {Biomaterial Investigations in Dentistry},
year = {2026},
volume = {13},
pages = {261--270},
doi = {10.2340/biid.v13.45702}
}
EUVIMED